Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population
A Real-World Comparison of CAR T-Cell Therapy Versus a Historical Standard-of-Care Approach for Relapsed-Refractory Large B-Cell Lymphoma in Ontario, Canada
1 activities
A Real-World Comparison of CAR T-Cell Therapy Versus a Historical Standard-of-Care Approach for Relapsed-Refractory Large B-Cell Lymphoma in Ontario, Canada
A Retrospective Claims Analysis of Real-World Treatment Patterns and Economic Burden Among Patients with Marginal Zone Lymphoma in the US
1 activities
A Retrospective Claims Analysis of Real-World Treatment Patterns and Economic Burden Among Patients with Marginal Zone Lymphoma in the US
Atrial Fibrillation Management and Outcomes in Bruton’s Tyrosine Kinase Inhibitor Treated Chronic Lymphocytic Leukemia Patients
1 activities
Atrial Fibrillation Management and Outcomes in Bruton’s Tyrosine Kinase Inhibitor Treated Chronic Lymphocytic Leukemia Patients
Barriers to CAR-T Therapy Adoption: Comparing Access in Academic and Community Settings in the US
1 activities
Barriers to CAR-T Therapy Adoption: Comparing Access in Academic and Community Settings in the US
Body Mass Index and Clinical Associations in Australasian Lymphoma Patients: A Lymphoma and Related Diseases Registry Study
1 activities
Body Mass Index and Clinical Associations in Australasian Lymphoma Patients: A Lymphoma and Related Diseases Registry Study
Comparative Analysis of Mortality from Serious Adverse Events Associated with CAR-T Therapies
1 activities
Comparative Analysis of Mortality from Serious Adverse Events Associated with CAR-T Therapies
Comparison of Treatment Outcomes with V-EPOCH Vs DA-EPOCH for First-Line Plasmablastic Disease
1 activities
Comparison of Treatment Outcomes with V-EPOCH Vs DA-EPOCH for First-Line Plasmablastic Disease
Comparison of Zanubrutinib and Ibrutinib As Treatments for Waldenstrom Macroglobulinemia: A Real-World Retrospective Study
1 activities
Comparison of Zanubrutinib and Ibrutinib As Treatments for Waldenstrom Macroglobulinemia: A Real-World Retrospective Study
Disparities in Clinical Trial Participation Among Medicare Beneficiaries with Hematologic Malignancies from 2006 to 2019: A SEER-Medicare Analysis
1 activities
Disparities in Clinical Trial Participation Among Medicare Beneficiaries with Hematologic Malignancies from 2006 to 2019: A SEER-Medicare Analysis
Disparities in Phase II and III Clinical Trial Enrollment for Hematologic Malignancies
1 activities
Disparities in Phase II and III Clinical Trial Enrollment for Hematologic Malignancies
Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population
0 activities
Epcoritamab for Relapsed/Refractory B Cell Lymphoma – the Israeli Real-World Experience of a Compassionate Use Program
1 activities
Epcoritamab for Relapsed/Refractory B Cell Lymphoma – the Israeli Real-World Experience of a Compassionate Use Program
Food Insecurity and Cardiovascular Risk Among Survivors of Pediatric Hematologic Malignancies
1 activities
Food Insecurity and Cardiovascular Risk Among Survivors of Pediatric Hematologic Malignancies
Hodgkin Lymphoma Transformation in Patients Who Received No Prior Chemotherapy for CLL/SLL: Outcomes from a Multicenter Retrospective Study in the Modern Era of Therapy
1 activities
Hodgkin Lymphoma Transformation in Patients Who Received No Prior Chemotherapy for CLL/SLL: Outcomes from a Multicenter Retrospective Study in the Modern Era of Therapy
Identifying the Barriers of Clinical Trial Access after CAR T-Cell Therapy in Relapsed/Refractory Large B-Cell Lymphoma
1 activities
Identifying the Barriers of Clinical Trial Access after CAR T-Cell Therapy in Relapsed/Refractory Large B-Cell Lymphoma
Impact of Novel Therapies (NTs) on Real-World (RW) Clinical Outcomes of Patients (pts) with Relapsed/Refractory (RR) Mantle-Cell Lymphoma (MCL) By Race/Ethnicity and TP53 Mutation Status
1 activities
Impact of Novel Therapies (NTs) on Real-World (RW) Clinical Outcomes of Patients (pts) with Relapsed/Refractory (RR) Mantle-Cell Lymphoma (MCL) By Race/Ethnicity and TP53 Mutation Status
Impact of Protein Energy Malnutrition on Hospitalized Patients with Hodgkin’s Lymphoma: A United States Population-Based Cohort Study
1 activities
Impact of Protein Energy Malnutrition on Hospitalized Patients with Hodgkin’s Lymphoma: A United States Population-Based Cohort Study
Impact of the Diagnosis-to-Treatment Interval (DTI) on Outcomes in Older Adults with Diffuse Large B-Cell Lymphoma (DLBCL) Treated in the Real-World Setting
1 activities
Impact of the Diagnosis-to-Treatment Interval (DTI) on Outcomes in Older Adults with Diffuse Large B-Cell Lymphoma (DLBCL) Treated in the Real-World Setting
Modeling Longitudinal Quality of Life Changes in Patients Diagnosed with Lymphomas: Heatmap Analysis of Electronic Patient-Reported Outcomes (ePRO) Data from the Bison-PRO Quality of Life Study
1 activities
Modeling Longitudinal Quality of Life Changes in Patients Diagnosed with Lymphomas: Heatmap Analysis of Electronic Patient-Reported Outcomes (ePRO) Data from the Bison-PRO Quality of Life Study
Mortality after Diagnosis of Cardiovascular Disease in Survivors of Adolescent and Young Adult Lymphoma
1 activities
Mortality after Diagnosis of Cardiovascular Disease in Survivors of Adolescent and Young Adult Lymphoma
Overall Survival Associated with Real-World Treatment Sequences in Patients with CLL/SLL in the United States
1 activities
Overall Survival Associated with Real-World Treatment Sequences in Patients with CLL/SLL in the United States
Pattern of IgG Testing and Immunoglobulin-Replacement Therapy in Patients with Non-Hodgkin Lymphoma
1 activities
Pattern of IgG Testing and Immunoglobulin-Replacement Therapy in Patients with Non-Hodgkin Lymphoma
Population-Based Registry Data over 15 Years Suggests Comparable Overall Survival for CLL Patients Treated with Chemoimmunotherapy and Targeted Therapies As First-Line Treatments
1 activities
Population-Based Registry Data over 15 Years Suggests Comparable Overall Survival for CLL Patients Treated with Chemoimmunotherapy and Targeted Therapies As First-Line Treatments
Primary Results of Patient-Reported Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) Versus Rituximab Plus GemOx (R-GemOx) from the Phase III Starglo Study
1 activities
Primary Results of Patient-Reported Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) Versus Rituximab Plus GemOx (R-GemOx) from the Phase III
Quality of Life during Survivorship Following Autologous Stem Cell Transplant for Mantle Cell Lymphoma
1 activities
Quality of Life during Survivorship Following Autologous Stem Cell Transplant for Mantle Cell Lymphoma
Real World Evidence of Tirabrutinib As a Salvage Treatment in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma in Taiwan: A Multicenter Study
1 activities
Real World Evidence of Tirabrutinib As a Salvage Treatment in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma in Taiwan: A Multicenter Study
Real-World (RW) Outcomes for Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients (Pts) with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) By High-Risk Features and Prior Treatments: Updated Evidence from the CIBMTR® R...
1 activities
Real-World (RW) Outcomes for Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients (Pts) with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) By High-Risk Features and Prior Treatments: Updated Evidence from the
Real-World Bleeding Risk, Outcomes and Treatment Patterns of Patients with CLL/SLL Receiving BTKi with or without Prescription Anticoagulants or Antiplatelets
1 activities
Real-World Bleeding Risk, Outcomes and Treatment Patterns of Patients with CLL/SLL Receiving BTKi with or without Prescription Anticoagulants or Antiplatelets
Real-World Data Shows Increased Incidence of Autoimmune Disease in Survivors of Childhood Lymphoid Malignancies
1 activities
Real-World Data Shows Increased Incidence of Autoimmune Disease in Survivors of Childhood Lymphoid Malignancies
Real-World Risk of Major Bleeding Events in BTKi-Treated Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
1 activities
Real-World Risk of Major Bleeding Events in BTKi-Treated Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
Richter Transformation (RT) in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): A Comparison of Two Eras
1 activities
Richter Transformation (RT) in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): A Comparison of Two Eras
Safety Profile of Infectious Events for First-Line Pola-R-CHP Therapy in Elderly Patients with Diffuse Large B-Cell Lymphoma Including Those 80+ Years Old in Japan
1 activities
Safety Profile of Infectious Events for First-Line Pola-R-CHP Therapy in Elderly Patients with Diffuse Large B-Cell Lymphoma Including Those 80+ Years Old in Japan
Sex, Race and Geographic Disparities in Early Age at Onset Hematologic Malignancies
1 activities
Sex, Race and Geographic Disparities in Early Age at Onset Hematologic Malignancies
Statins May Improve Outcomes and Toxicities in Patients Undergoing CD19-Specific CAR T-Cell Therapy for Aggressive B-Cell Lymphomas
1 activities
Statins May Improve Outcomes and Toxicities in Patients Undergoing CD19-Specific CAR T-Cell Therapy for Aggressive B-Cell Lymphomas
Survival Disparities Among Overweight and Obese Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia in a Large Integrated Healthcare System
1 activities
Survival Disparities Among Overweight and Obese Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia in a Large Integrated Healthcare System
Timing of End-of-Treatment PET Scans and Impact on Subsequent Testing in Diffuse Large B-Cell Lymphoma
1 activities
Timing of End-of-Treatment PET Scans and Impact on Subsequent Testing in Diffuse Large B-Cell Lymphoma
Trends and Disparities in Acute Lymphoblastic Leukemia-Related Mortality in the United States from 1999 to 2020: Insights from the CDC Wonder Database
1 activities
Trends and Disparities in Acute Lymphoblastic Leukemia-Related Mortality in the United States from 1999 to 2020: Insights from the CDC Wonder Database
Trends in Incidence and Survival of Patients with Primary Effusion Lymphoma in the United States
1 activities
Trends in Incidence and Survival of Patients with Primary Effusion Lymphoma in the United States
Utility of PET/CT Imaging in Predicting Outcomes of Patients with Lymphoid Malignancy-Associated Hemophagocytic Lymphohistiocytosis: A Retrospective Analysis from a Single Tertiary Center
1 activities
Utility of PET/CT Imaging in Predicting Outcomes of Patients with Lymphoid Malignancy-Associated Hemophagocytic Lymphohistiocytosis: A Retrospective Analysis from a Single Tertiary Center